4-((4-(4-Chloro-3-(trifluoromethyl)phenoxy)-3,5-difluorobenzyl)-oxy)-1-methyl-6-morpholinopyrimidin-2(1H)-one

ID: ALA3794023

Chembl Id: CHEMBL3794023

PubChem CID: 121448368

Max Phase: Preclinical

Molecular Formula: C23H19ClF5N3O4

Molecular Weight: 531.87

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  Cn1c(N2CCOCC2)cc(OCc2cc(F)c(Oc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)nc1=O

Standard InChI:  InChI=1S/C23H19ClF5N3O4/c1-31-20(32-4-6-34-7-5-32)11-19(30-22(31)33)35-12-13-8-17(25)21(18(26)9-13)36-14-2-3-16(24)15(10-14)23(27,28)29/h2-3,8-11H,4-7,12H2,1H3

Standard InChI Key:  AWWXPCCSNMKHGY-UHFFFAOYSA-N

Alternative Forms

  1. Parent:

    ALA3794023

    ---

Associated Targets(Human)

PLA2G7 Tchem LDL-associated phospholipase A2 (1338 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Liver (3974 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Liver (4264 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 531.87Molecular Weight (Monoisotopic): 531.0984AlogP: 4.94#Rotatable Bonds: 6
Polar Surface Area: 65.82Molecular Species: NEUTRALHBA: 7HBD: 0
#RO5 Violations: 1HBA (Lipinski): 7HBD (Lipinski): 0#RO5 Violations (Lipinski): 1
CX Acidic pKa: CX Basic pKa: CX LogP: 4.94CX LogD: 4.94
Aromatic Rings: 3Heavy Atoms: 36QED Weighted: 0.42Np Likeness Score: -1.32

References

1. Chen X, Wang K, Xu W, Ma Q, Chen M, Du L, Mo M, Wang Y, Shen J..  (2016)  Discovery of Potent and Orally Active Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) Inhibitors as a Potential Therapy for Diabetic Macular Edema.,  59  (6): [PMID:26927682] [10.1021/acs.jmedchem.5b01930]

Source